Voyager Therapeutics, Inc. (VYGR)
|Net Income (ttm)||-59.83M|
|Day's Range||5.86 - 6.10|
|52-Week Range||2.46 - 10.60|
|Price Target||6.73 (+12.5%)|
|Earnings Date||Aug 8, 2022|
Voyager Therapeutics, Inc., a gene therapy company, focuses on the development of treatments and next-generation platform technologies. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1 clinical trial for the treatment of Parkinson's disease. Its preclinical programs comprise VY-SOD102 for the treatment of amyotrophic lateral sclerosis; VY-HTT01 for Huntington's disease; VY-FXN01 for Friedreich's ataxia; and Tau program for the treatment of tauopathies, including Alzheimer's disease, progressive supranuclear p... [Read more...]
Financial PerformanceFinancial Statements
According to 14 analysts, the average rating for VYGR stock is "Buy." The 12-month stock price forecast is 6.73, which is an increase of 12.54% from the latest price.
Voyager customer lost $1 million saved over 24 years and is one of many now desperate to recoup funds
Voyager Digital had 3.5 million customers, and many are now doing everything they can to try and get some of their money back.
Court proceedings and financial documents detail how complicated relationships were between the two Bankman-Fried firms — Alameda and FTX — and Voyager Digital.
Voyager Therapeutics (VYGR) delivered earnings and revenue surprises of 10.71% and 71.52%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Voyager Therapeutics Prioritizes Pipeline and Reports Second Quarter 2022 Financial and Operating Results
Pipeline prioritizes tau antibody for Alzheimer's disease and gene therapies for GBA1 Parkinson's disease and SOD1 ALS, each program employing efficient paths to human proof of biology
Voyager Therapeutics Presents New Data Demonstrating Novel Candidate Therapeutic Antibodies Reduced Tau Pathology in ...
Novel passive antibodies bind to paired helical filamentous tau and inhibit propagation of pathological tau
CAMBRIDGE, Mass., Aug. 02, 2022 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a gene therapy and neuroscience company developing life-changing treatments and next-generation adeno-assoc...
CAMBRIDGE, Mass., July 28, 2022 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a gene therapy company developing life-changing treatments and next-generation adeno-associated virus (AAV)...
Voyager Therapeutics' TRACER™ Capsids Demonstrate Enhanced CNS Transduction Across Species; New Preclinical Results B...
VCAP-102 capsid achieved respective 60-fold and 50-fold improvements in brain transduction in non-human primates and mice compared to conventional AAV9 capsids with IV dosing
Voyager Therapeutics to Present Preclinical Data from its Vectorized anti-HER2 Antibody Program and a Novel AAV5-Deri...
Single dose of TRACER AAV vector encoding anti-HER2 antibody reduced CNS tumor burden and extended survival across multiple mouse models of breast cancer brain metastasis
Voyager Therapeutics (VYGR) delivered earnings and revenue surprises of -300% and 97.67%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Company to present new data at the American Society for Gene and Cell Therapy (ASGCT) Annual Meeting highlighting cross-species translatability and CNS tropisms of novel TRACER™ AAV9- and AAV5-derived ...
Voyager Therapeutics Announces Multiple Data Presentations at the American Society of Gene and Cell Therapy 2022 Annu...
CAMBRIDGE, Mass., May 03, 2022 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ: VYGR), a gene therapy company developing life-changing treatments and next-generation adeno-associated virus (AAV) ...
Voyager Therapeutics (VYGR) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the nea...
Does Voyager Therapeutics (VYGR) have what it takes to be a top stock pick for momentum investors? Let's find out.
Are these high-flying stocks smart picks to buy now?
Shares of Voyager Therapeutics Inc. VYGR, +7.45% gained 2.9% in premarket trading on Tuesday after the gene therapy company said it hired former Biogen Inc. BIIB, -0.84% executive Dr. Alfred Sandrock Jr...
Renowned neuroscientist brings pioneering drug development expertise and vision to emerging leader in next-generation AAV gene therapy Renowned neuroscientist brings pioneering drug development expertis...
Voyager Therapeutics has promising technology. But the stock is very risky.
Voyager Therapeutics (VYGR) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more ...
Is it a good or bad thing when a stock experiences a golden cross technical event?
License option agreement with Novartis for target-specific access to TRACER™ next-generation AAV capsids for potential use with three CNS targets plus options to access capsids for two additional targets
Novartis AG (NYSE: NVS) has entered a license option agreement with Voyager Therapeutics Inc (NASDAQ: VYGR) for three capsids to use in potential gene therapies for neurological diseases, with an option...
Voyager Therapeutics Announces License Option Agreement with Novartis for Target-Specific Access to Next-Generation T...
Voyager receives $54 million upfront with potential option exercise fees and milestone payments of up to $1.7 billion plus product sales-based royalties
Voyager Therapeutics (VYGR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
CAMBRIDGE, Mass., Feb. 10, 2022 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR) a gene therapy company developing life-changing treatments and next-generation adeno-associated virus (AAV) ...